Marshall Wace North America’s Xenon Pharmaceuticals XENE Stock Holding History

Marshall Wace North America’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$5.17M	Sell	338,301 -72,958	-18%	-$1.27M	0.02%	499
2021 Q2	$7.66M	Buy	+411,259	New	+$7.58M	0.03%	428
2020 Q4	–	Sell	-24,531	Closed	-$272K	–	1623
2020 Q3	$272K	Sell	24,531 -6,475	-21%	-$76.2K	﹤0.01%	1085
2020 Q2	$389K	Buy	31,006 +6,194	+25%	+$78.8K	﹤0.01%	968
2020 Q1	$282K	Buy	24,812 +9,873	+66%	+$141K	﹤0.01%	858
2019 Q4	$196K	Buy	+14,939	New	+$157K	﹤0.01%	970

Other funds holding XENE

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Marshall Wace North America's XENE Position: Q3 2021 in Review

Marshall Wace North America reduced its Xenon Pharmaceuticals (XENE) stake by 18% in Q3 2021, selling an estimated $1.27M and leaving 338,301 shares worth $5.17M. The position accounts for 0.02% of the portfolio, ranked #499.

Marshall Wace North America first reported a position in XENE in Q4 2019 and has held it in 6 quarters since. The position peaked at $7.66M in Q2 2021. 118 funds tracked by Wall St. Rank hold XENE as of Q3 2021.

Marshall Wace North America held 338,301 shares of Xenon Pharmaceuticals worth $5.17M as of Q3 2021.
Marshall Wace North America sold 72,958 Xenon Pharmaceuticals shares in Q3 2021, an estimated $1.27M.
Xenon Pharmaceuticals made up 0.02% of Marshall Wace North America's portfolio in Q3 2021, its #499 holding.
Marshall Wace North America first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 6 quarters since.
Marshall Wace North America's Xenon Pharmaceuticals position peaked at $7.66M in Q2 2021.
118 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.